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ORIGINAL ARTICLE
Background/Aims: The efficacy and safety of a combination of ezetimibe and low-dose statin as primary
treatment for dyslipidemia in renal transplant patients were evaluated prospectively.
Methods: The study enrolled 77 renal transplant recipients with dyslipidemia. They were given ezetimibe (10 mg)
and simvastatin (10 mg) for 6 months as the initial treatment for dyslipidemia. Efficacy and safety were evaluated
using lipid profiles, trough calcineurin inhibitor levels, allograft function, and adverse effects. The effects on
proteinuria and high sensitivity C-reactive protein (hsCRP) levels were also evaluated. 
Results: Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%),
triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached
the target LDL-C level of <100 mg/dL. No significant change in the trough calcineurin inhibitor levels or allograft
function occurred, and no serious adverse effects were observed. Fourteen patients (18.2%) discontinued
treatment; eight patients (11.7%) developed muscle pain or weakness without an increase in creatinine kinase
levels, and two patients (2.6%) developed elevated liver transaminase levels. The proteinuria and hsCRP levels
did not change significantly. 
Conclusions: Ezetimibe and low-dose statin treatment is safe and effective as a primary treatment for dyslipidemia
in renal transplant patients. (Korean J Intern Med 2009;24:233-237)
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INTRODUCTION
Dyslipidemia, a major complication in renal transplant
patients, increases the risk of cardiovascular disease
(CVD) [1,2], which is a major cause of morbidity and
mortality in the renal transplant population [3]. The
clinical practice guidelines of the National Kidney
Foundation Work Group recommend a target low-density
lipoprotein cholesterol (LDL-C) level of less than 100 mg
/dL [4], and the use of a statin as the first-line treatment.
Nevertheless, in clinical practice, many patients fail to
reach the target LDL-C level. The reasons for this may be
multifactorial, but include a tendency to reduce the statin
dose because of concerns about the adverse effects related
to higher doses and drug interactions between the statin
and calcineurin inhibitors (CNIs) [4,5].
Ezetimibe lowers cholesterol levels by inhibiting the
intestinal absorption of cholesterol [6] so ezetimibe is
especially useful for patients who are statin-intolerant or
resistant to high-dose statin monotherapy [7]. The
incremental lipid-lowering effect of ezetimibe has been
observed in both non-transplant [8-18] and renal transplantpopulations [19-22]. However, no report has examined
the use of ezetimibe combined with a low-dose statin as
the initial treatment in renal transplant patients.
This study prospectively evaluated the efficacy and
safety of ezetimibe and low-dose simvastatin therapy as
primary treatment for dyslipidemia in renal transplant
recipients. Our results revealed that primary treatment of
renal transplant recipients with ezetimibe and low-dose
simvastatin lowers lipid levels dramatically without
significant adverse reactions. 
METHODS
Study population
A prospective study examined renal transplant
recipients receiving a single combination tablet of
ezetimibe (10 mg) and simvastatin (10 mg) daily. The
inclusion criteria were the passage of at least 4 months
after renal transplantation, fasting LDL-C levels over
100 mg/dL despite therapeutic lifestyle changes, and
informed consent of the patient. Patients who had one or
more of the following criteria were excluded: use of other
lipid-lowering drugs (including statin monotherapy)
within 4 weeks of the start of ezetimibe and simvastatin
therapy, an episode of unstable angina or myocardial
infarction within the past 6 months, preexisting malig-
nancy with a life expectancy of less than 1 year, abnormal
liver enzymes (aspartate aminotransferase [AST] or
alanine aminotransferase [ALT]) ≥2× the upper limit of
normal, and pregnant or breast-feeding women.
Study protocol
After a 1-month screening period, eligible patients
were enrolled in the study. The doses of simvastatin and
ezetimibe were not changed during the study period.
Study visits were scheduled before initiating treatment
and after 2 weeks and 1, 3, and 6 months. Fasting lipid
profiles (total cholesterol [TC], triglyceride [TG], LDL-C,
and high-density lipoprotein cholesterol [HDL-C]),
creatinine kinase (CK), and trough immunosuppressant
levels (cyclosporin A [CsA], tacrolimus [Tac], and sirolimus
[SRL]) were measured at all scheduled visits. The urine
protein-to-creatinine ratio in a spot urine sample, liver
transaminase (AST, ALT), and high sensitivity C-reactive
protein (hsCRP) were measured before initiating
treatment and after 1, 3, and 6 months. Adverse drug
reactions, such as myalgia and skin rash, were monitored
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Table 1. Patient characteristics (n=77)
Variables
Age, years 45 (24-64)
Female gender  39 (50.6)
Months after transplantation  40 (4-158)
Estimate GFR, mL/min/1.73 m
2 58.0 (17.4-87.6)
Body weight, kg 60.5 (43-86)
Body mass index, kg/m
2 22.6 (17-33)
Main immunosuppressive drug
CsA 43 (55.8)
Tac 31 (40.3)
SRL 3 (3.9)
Type of transplant
Living donor 60 (77.9)
Deceased donor 17 (22.1)
Cause of end-stage renal disease 
Chronic glomerulonephritis 44 (57.1)
Diabetes 7 (9.1)
Hypertension 6 (7.8)
Others 20  (26.0)
Dialysis before transplant
Hemodialysis 60 (77.9)
Peritoneal dialysis 15 (19.5)
None 1 (1.3)
Unknown 1 (1.3)
Values are the median (range) or number (percentage).
GFR, glomerular filtration rate; CsA, cyclosporine; Tac,
tacrolimus; SRL, sirolimus.
Table 2. Overall effect of ezetimibe and low-dose simvastatin therapy on lipid profiles, allograft function,
proteinuria, and hsCRP (n=63)
Before therapy After therapy p
TC, mg/dL 247 (220-412) 161 (109-263) <0.001
TG, mg/dL 152 (51-510) 124 (41-415) <0.001
LDL-C, mg/dL 149 (123-300) 80 (44-160) <0.001
HDL-C, mg/dL 60 (4-109) 57 (24-100) 0.906
eGFR, mL/min/1.73 m
2 56.3±14.9 55.0±15.6 0.093
Urine protein-to-creatinine ratio, mg/g 226.0 (51.5-5985.5) 180.3 (57.5-6857.1) 0.341
hsCRP, mg/dL 0.1 (0-1.0) 0.1 (0-2.2) 0.695
Values are the median (range) or mean±SD.
hsCRP, high sensitivity C-reactive protein; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C,
high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate.at all scheduled visits. Treatment compliance was assessed
after 1, 3, and 6 months. The study protocol was approved
by the institutional review board.
Data and statistical analysis
The following variables were analyzed before and after
ezetimibe and low-dose simvastatin treatment: fasting
lipid profiles (TC, TG, LDL-C, and HDL-C), estimated
glomerular filtration rate (eGFR), urine protein-to-
creatinine ratio in a spot urine sample, liver transaminase
(AST, ALT), hsCRP, CK, trough immunosuppressant
levels (CsA, Tac, and SRL), and adverse drug reactions.
LDL-C was calculated using Friedewald’s equation (LDL-
C=TC-[TG/5]-[HDL-C] and eGFR was calculated using
the abbreviated Modification of Diet and Renal Disease
(MDRD) equation [23].
Continuous data are presented as the median and range
or mean±SD and were compared using the paired t-test.
In a subgroup analysis of patients with proteinuria (≥500
mg/g) or high hsCRP levels (≥0.5 mg/dL), data including
proteinuria and hsCRP levels were compared using the
Wilcoxon signed-rank test.
RESULTS
Patient characteristics
Seventy-seven patients were enrolled in this study. The
patient characteristics are summarized in Table 1. Three
patients were on CNI-free regimens (SRL and prednisolone)
and two patients were on corticosteroid-free regimens
(CsA and mycophenolate mofetil). Fifty-six patients were
on a triple immunosuppressive regimen and 21 patients
were on a dual immunosuppressive regimen. Sixty-three
patients (81.8%) continued on ezetimibe and low-dose
simvastatin therapy for the full 6 months.
Effects of ezetimibe and low-dose simvastatin on
lipid panels
The overall effects of treatment on the fasting lipid
profiles are shown in Table 2. The TC, TG, and LDL-C
levels were reduced significantly after treatment with
mean percentage changes of 34.6±9.5, 16.0±27.4, and
47.6±13.7%, respectively. After 6 months of treatment, 52
patients (82.5%) reached the target of LDL-C <100
mg/dL.
An analysis of subgroups divided according to the
type of CNI showed that the lipid-lowering effect was
significant in both the CsA and Tac groups (Table 3). In
CsA-treated patients, the levels of TC, TG, and LDL-C
were reduced significantly with mean percentage changes
of 33.9±6.5, 12.0±29.5, and 47.2±9.9%, respectively. In
Tac-treated patients, the TC, TG, and LDL-C levels were
significantly reduced with mean percentage changes of
35.8±12.0, 21.4±24.5, and 48.8±16.7%, respectively.
Stable trough CsA and Tac levels were maintained. One
patient was on SRL and had a trough level of 8.9 ng/mL
before treatment and 9.5 ng/mL after treatment.
Effect of ezetimibe and low-dose simvastatin therapy
on allograft function, proteinuria, and hsCRP levels
As shown in Table 2, no significant change occurred in
the eGFR, urine protein-to-creatinine ratio, or hsCRP
concentration after treatment. In a subgroup analysis of
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Table 3. Effect of ezetimibe and low-dose simvastatin therapy on lipid profiles according to CsA and Tac
Before therapy After therapy p
CsA group (n=33) 
TC, mg/dL 251 (223-412) 169 (124-222) <0.001
TG, mg/dL 136 (51-510) 123 (41-312) 0.014
LDL-C, mg/dL 152 (123-300) 83 (44-133) <0.001
HDL-C, mg/dL 60 (37-109) 61 (29-100) 0.829
CsA, ng/mL 101.7 (24-182) 99.7 (33.5-202.6) 0.301
Tac group (n=29) 
TC, mg/dL 238 (220-315) 152 (109-263) <0.001
TG, mg/dL 158 (61-429) 124 (41-415) 0.001
LDL-C, mg/dL 147 (124-204) 72 (46-160) <0.001
HDL-C, mg/dL 57 (4-89) 56 (24-78) 0.675
Tac, ng/mL 5.0 (2.0-10.0) 4.9 (2.5-18.7) 0.124
Values are the median (range).
CsA, cyclosporine; Tac, tacrolimus; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-
density lipoprotein cholesterol.patients with proteinuria of at least 500 mg/g (n=16), the
median urine protein-to-creatinine ratio was reduced
from 1558.5 (range 500.4-5985.5) to 869.5 (range 93.2-
6857.1) mg/g, but the difference was not significant
(p=0.14). In a subgroup analysis of patients with hsCRP
levels ≥0.5 mg/dL (n=6), the median hsCRP concen-
tration was reduced from 0.7 (range 0.5-1.0) to 0.3 (range
0.02-2.2) mg/dL, but statistical significance was not
achieved (p= 0.6).
Adverse drug reactions
Fourteen patients (18.2%) discontinued the ezetimibe
and low-dose simvastatin treatment. The most common
reason was muscle pain or weakness (n=8, 11.7%) without
a significant increase in CK levels. Two patients (2.6%)
had greater than twofold increases in the upper limit
levels of AST and ALT. Other reasons were skin rash,
dizziness, pregnancy, and concomitant administration of
itraconazole.
DISCUSSION
Our results clearly demonstrate the lipid-lowering
efficacy of a combination of ezetimibe and low-dose statin
in renal transplant recipients with dyslipidemia. Four
reports on the lipid-lowering efficacy of ezetimibe in
renal transplant patients have been published [19-22],
but these studies focused mainly on patients who were
statin-intolerant or resistant to high-dose statin monother-
apy. Compared to previous reports, our study provides
evidence of the potential advantage of the combination of
ezetimibe and low-dose statin as the initial treatment for
dyslipidemia in this population.
The most important finding of this study is that
treatment with a combination of ezetimibe and low-
dose statin effectively lowered the LDL-C level in renal
transplant recipients. With ezetimibe (10 mg) and sim-
vastatin (10 mg), the LDL-C level was reduced 47.6% on
average and 82.5% of the patients reached the LDL-C
goal of <100 mg/dL (Table 2). Our results (47.6% reduction
in the LDL-C level) are better than those of a study on
statin monotherapy (fluvastatin, 40 mg) in a large number
of renal transplant patients (32% reduction in the LDL-C
level) [24]. Furthermore, we obtained better results than
studies reporting an average 31% reduction (range 22-
41%) in the LDL-C level using ezetimibe with or without
high-dose statin treatment [19-22]. The reason for the
enhanced lipid-lowering effect seen in our study may be
explained partially by the higher pretreatment LDL-C
levels [20,22]. Nevertheless, it suggests that initial
treatment with ezetimibe and low-dose statin has a
more potent lipid-lowering effect than other regimens,
such as statin monotherapy or the secondary addition
of ezetimibe to a statin. This presumption is supported
by the excellent results (45-54%) in non-transplant
patients initially treated with ezetimibe and a statin
[11-13,16,18].
In addition to its excellent effect on dyslipidemia, renal
transplant patients receiving a CNI would benefit from
ezetimibe and low-dose statin therapy. The effective dose
of ezetimibe is higher in patients receiving CsA than in
patients not receiving CsA [25-27]. The mechanism of
the interaction between ezetimibe and CsA is not fully
understood, but CsA is thought to alter the glucuronidation
of ezetimibe in gastrointestinal tissue, which alters the
pharmacokinetics of ezetimibe and its metabolites [27].
Therefore, patients on CsA may have a higher lipid-
lowering effect with lower doses of ezetimibe than those
not receiving CsA.
Another advantage of the combination treatment with
ezetimibe and low-dose statin is safety. In this study, the
incidence of adverse reactions associated with statins was
quite low. Only 2.6% of the patients developed elevated
transaminase levels, which is a rate similar to that in the
non-transplant population [28]. Muscle pain or weakness
occurred in 11.7% of the patients, but it was nonspecific
and was not associated with increased CK levels. The
blood trough CNI levels and allograft function measured
using the estimated GFR were stable during the 6-month
treatment. This suggests that combination treatment with
ezetimibe and low-dose statin has fewer adverse effects
and induces less allograft dysfunction than high-dose
statin therapy.
Our study has some limitations. First, it lacks random-
ization to compare ezetimibe plus low-dose statin with
high-dose statin monotherapy. Second, the observation
period was short and the study population was relatively
small, which meant that we did not observe a beneficial
effect of statin on reducing proteinuria or hsCRP levels.
In conclusion, the combination of ezetimibe and low-
dose statin is an effective primary lipid-lowering therapy
in renal transplant patients. This treatment may help
more transplant patients to achieve the optimal LDL-C
target compared to statin monotherapy.
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